65,436 11% 281,205 246,809 14% (1) Other income (expense), net 229 218 230 (0)% 981 1,432 (32)% Total Revenue 72,833 71,878 65,665 11% 282,186 248,241 14% (2) Cost of sales 59,992 61,567 56,037 7% 237,391
Ventures 1st Quarter 2019 MD&A 1 Indorama Ventures Public Company Ltd Management Discussion and Analysis 1st Quarter 2019 Highlights Revenue $3.0 billion (THB 95.8 billion), +26% YoY Core EBITDA of $304
Indorama Ventures 1st Quarter 2019 MD&A 1 Indorama Ventures Public Company Ltd Management Discussion and Analysis 1st Quarter 2019 Highlights Revenue $3.0 billion (THB 95.8 billion), +26% YoY Core EBITDA
% LTM 3Q18 LTM 3Q17 LTM YoY% Reported Financials Net sales 96,001 83,591 72,605 32% 326,152 281,205 16% Other income (expense), net1 263 303 229 15% 2,090 981 113% Total Revenue 96,263 83,893 72,833 32
quarter driven by resilient sales and margins in Integrated PET, USA PX and PIA businesses. Core net profit grew to THB 1.6B • Core EBITDA grew in all segments and in all regions as our products primarily
subsidiary for Quarter 1 of 2018 ending on 31 March 2018 as follows; Statements of Comprehensive Income Revenue from Hospital Operations The Company generated the revenue from hospital operations for the 1st
its subsidiaries would like to report the operating results for the year ended December 31, 2019. According to the consolidated financial statements, total revenue recorded at 1,396.75 million which is
to the following reasons: Unit: Million Baht - The cash-base patients’ revenue for Q2/2018 were Baht 1,240 million which increased from the Q2/2017 by Baht 190.6 million or 18.2% as a result of the
11.6% due to the following reasons: Unit: Million Baht - The cash-base patients’ revenue for Q3/2018 were Baht 1,474.0 million which increased from Q3/2017 by Baht 201.9 million or 15.9% as a result of
million or 11.6% due to the following reasons: Unit: Million Baht - The cash-base patients’ revenue for Q3/2018 were Baht 1,518.9 million which increased from Q3/2017 by Baht 245.3 million or 19.3% as a